Radix Partners joins the “Happy Cell Factory” Network to Support the Commercialisation of Cell and Gene Therapy Manufacturing Platform.

Allmersbach im Tal / Aachen / London — 21.01.2026 —

Radix Partners today announced its involvement in the Happy Cell Factory (HCF), an integrated manufacturing platform designed to enable true industrial-scale production of Cell and Gene Therapies (CGT), jointly developed by Harro Höfliger and the Fraunhofer Institute for Production Technology IPT.

With Radix Partners joining the established partnership between Harro Höfliger and Fraunhofer IPT, the collaboration brings together world-class engineering, leading applied research, and deep CGT operational expertise to advance the HCF vision from concept to market-ready reality. Radix Partners will provide strategic and operational support to help position and implement the HCF as a next-generation platform that delivers scalable, economically sustainable CGT manufacturing.

The initiative unites complementary capabilities across development and commercialisation. Harro Höfliger contributes its globally recognised leadership in engineering and pharmaceutical automation, offering modular, precision-built manufacturing systems designed for commercial-scale throughput. Fraunhofer IPT brings world class applied research excellence in bioprocess development, digitalisation, and advanced production and automation technologies. Radix Partners adds end-to-end CGT operational expertise, spanning CMC leadership, manufacturing strategies and supply chain integration, cost-of-goods optimisation and commercial readiness.

Together, Harro Höfliger and Fraunhofer IPT, supported by Radix Partners, will advance the Happy Cell Factory as both a demonstrator and an operational blueprint for automated, closed, and standardised end-to-end CGT manufacturing. The platform will feature digitally connected production systems capable of real-time monitoring, intelligent scheduling, and advanced analytics. It will also be structured around economically optimised manufacturing layouts and process flows aligned with commercial cost structures, while offering a scalable, transferable, and regulatory-ready framework suitable for global deployment.

By integrating engineering innovation, applied research, CGT economics, and late-stage operational design from the outset, the collaboration aims to address several long-standing barriers that have constrained the field. These include high manufacturing costs, limited scalability, labour-intensive processing, fragmented clinical-to-commercial supply chains, and challenges in process consistency and technology transfer.

The Happy Cell Factory will provide therapy developers, CDMOs, and industry stakeholders with a platform to evaluate and adopt industrialised, economically viable manufacturing solutions that support broader patient access, long-term commercial growth, and moving the manufacturing of Cell and Gene Therapies to the next level in terms of scale and automation

Christian Kollecker, Director Sales Advanced Therapies of Harro Höfliger said: ”This collaboration builds on Harro Höfliger’s targeted investment in next-generation manufacturing solutions. By combining our end-to-end high-throughput automation technology and IPT’s applied research capabilities with Radix Partners end-to-end operational expertise, we aim to accelerate the creation and deployment of a Happy Cell Factory Commercial based on our HCF Lab and Pilot to transform and accelerate the development and commercialisation of Cell and Gene Therapies. This will set new industry standards, reduce cost of goods and enable therapy developers and CDMOs to manufacture reliably and at scale to the ultimate benefit of wider patient and market access.”

Cristian Cîrciumaru, Founder and Managing Director of Radix Partners said: ”We are thrilled to enter a collaboration agreement with Harro Höfliger and the Fraunhofer Institute for Production Technology. We’ve been very active in the future of CGT manufacturing topic and established ourselves as a thought leader early on. This partnership therefore marks recognition and a pivotal milestone in our mission to strengthen and evolve the end-to-end (E2E) operational value chain for CGT. We share a common long-term vision for creating future standards in manufacturing technology and working with HH and IPT will enable us to support hands-on the global deployment of the Happy Cell Factory platform with a common shared goal to help each and all patient(s) receive the therapy they deserve.“

Please visit Harro Höfliger and Fraunhofer Institute for Production Technology - Fraunhofer IPT and for more details.